Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.

@article{Cannavo2015DoesPT,
  title={Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.},
  author={Salvatore Cannavo and Fausto Bogazzi and Annamaria Colao and Laura de Marinis and Pietro Maffei and Roy Gomez and Eugenio Graziano and M. Monterubbianesi and Silvia Grottoli},
  journal={Journal of endocrinological investigation},
  year={2015},
  volume={38 10},
  pages={1099-109}
}
OBJECTIVE GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safety surveillance study of long-term pegvisomant treatment of patients with acromegaly. A noninterventional safety surveillance study in which safety and treatment outcomes of pegvisomant were evaluated on the basis of data… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.